Diabetes mellitus–induced microvascular destabilization in the myocardium
R Hinkel, A Howe, S Renner, J Ng, S Lee, K Klett… - Journal of the American …, 2017 - jacc.org
Background Diabetes mellitus causes microcirculatory rarefaction and may impair the
responsiveness of ischemic myocardium to proangiogenic factors. Objectives This study …
responsiveness of ischemic myocardium to proangiogenic factors. Objectives This study …
Predictive value of coronary computed tomography angiography in asymptomatic individuals with diabetes mellitus: systematic review and meta-analysis
Abstract Background Coronary CT angiography (CTA) is generally not established as a
screening tool for asymptomatic individuals. However, it is controversial whether this test …
screening tool for asymptomatic individuals. However, it is controversial whether this test …
Prognostic value of coronary computed tomography angiography in patients with diabetes: a meta-analysis
OBJECTIVE The usefulness of coronary computed tomography angiography (CTA) for the
evaluation of coronary artery disease (CAD) in patients with diabetes is ambiguous. We …
evaluation of coronary artery disease (CAD) in patients with diabetes is ambiguous. We …
Duration of diabetes and prediabetes during adulthood and subclinical atherosclerosis and cardiac dysfunction in middle age: the CARDIA study
OBJECTIVE To determine whether the duration of diabetes and duration of prediabetes
estimated during a 25-year period in early adulthood are each independently associated …
estimated during a 25-year period in early adulthood are each independently associated …
Long-term prognostic utility of coronary CT angiography in stable patients with diabetes mellitus
P Blanke, C Naoum, A Ahmadi, C Cheruvu… - JACC: Cardiovascular …, 2016 - jacc.org
Objectives: The goal of this study was to determine the long-term prognostic value of
coronary computed tomography angiography (CTA) among patients with diabetes mellitus …
coronary computed tomography angiography (CTA) among patients with diabetes mellitus …
[HTML][HTML] The coexistence of carotid and lower extremity atherosclerosis further increases cardio-cerebrovascular risk in type 2 diabetes
MF Li, CC Zhao, TT Li, YF Tu, JX Lu, R Zhang… - Cardiovascular …, 2016 - Springer
Background Both carotid and lower limb atherosclerosis are associated with increased
cardiovascular and cerebrovascular risks. However, it is still unclear whether the …
cardiovascular and cerebrovascular risks. However, it is still unclear whether the …
[HTML][HTML] Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort …
Background We aimed to investigate the impact of diabetes duration and carotid artery
stenosis (CAS) on the occurrence of major adverse cardiovascular events (MACE) in …
stenosis (CAS) on the occurrence of major adverse cardiovascular events (MACE) in …
[HTML][HTML] Role of the scavenger receptor CD36 in accelerated diabetic atherosclerosis
M Navas-Madroñal, E Castelblanco… - International journal of …, 2020 - mdpi.com
Diabetes mellitus entails increased atherosclerotic burden and medial arterial calcification,
but the precise mechanisms are not fully elucidated. We aimed to investigate the implication …
but the precise mechanisms are not fully elucidated. We aimed to investigate the implication …
Coronary atherosclerosis across the Glycemic Spectrum among asymptomatic adults: the Miami heart Study at Baptist health South Florida
BACKGROUND: The contemporary burden and characteristics of coronary atherosclerosis,
assessed using coronary computed tomography angiography (CCTA), is unknown among …
assessed using coronary computed tomography angiography (CCTA), is unknown among …
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: a post hoc analysis of the LEADER and SUSTAIN 6 clinical trials
S Verma, SC Bain, T Monk Fries… - Diabetes, Obesity …, 2019 - Wiley Online Library
Cardiovascular risk reduction with liraglutide and semaglutide in patients with type 2
diabetes was demonstrated in the LEADER (ClinicalTrials. gov: NCT01179048) and …
diabetes was demonstrated in the LEADER (ClinicalTrials. gov: NCT01179048) and …